IntuitionLabs is now a member of the Claude Partner Network – AI training and upskilling with Claude for pharma and biotech. Book a call.
A 2026 guide to FDA PQ/CMC FHIR and ICH M16 readiness, with Stage 1 and Stage 2 profiles, source-system mappings, IDMP overlap, provenance controls, and validation criteria for structured Module 3 data.
A 2026 guide to DailyMed API v2 covering SET ID lineage, historical SPL downloads, pagination, identifier joins, Python retrieval, archive handling, and a reproducible label-change pipeline.
A 2026 analysis of Claude API on-demand compaction for pharma agents, covering signed blocks, current platform support, preserved thinking, critical-state regression tests, audit evidence, and measured token economics.
A 2026 implementation reference for CDISC ODM 2.0 migration, covering XML/JSON contracts, API evidence, backward compatibility, consumer matrices, validation tests, and archive preservation.
A 2026 comparison of Pinnacle 21, Nurocor and TCS ADD clinical metadata repositories, covering governance, CDISC coverage, study-build outputs, measured reuse, migration and a proof-of-concept script.
A 2026 data report on FDA PMR and PMC study status, original milestones, quarterly public-file limits, record identity, portfolio views, and an auditable tracking model.
A 2026 buyer guide to FlowJo 11, OMIQ, and Cytobank, with a matched-FCS pilot protocol, edition and licensing matrix, review controls, and a three-year cost worksheet.
A 2026 PMA eSTAR readiness guide covering the September draft, voluntary scope, designated supplements, version and attachment controls, center routing, screening, and a 30/60/90-day plan.
A 2026 guide to AccessGUDID API v3, record-key identity, version-aware schemas, daily and full-release ingestion, terminology enrichment, and reconciliation controls for medical device data.
2026 control matrix for Claude Managed Agents in GxP workflows: auto and always_ask outcomes, non-overridable denials, MCP versus custom tools, audit evidence, validation tests, and pilot metrics.
A 2026 antibody R&D comparison of Benchling Biologics, Genedata Biologics, and IDBS Polar across format modeling, registration, assay and sample lineage, interfaces, GxP, and a buyer-run proof of concept.
A 2026 protocol for validating CDISC Dataset-JSON 1.1 against XPT: canonical datasets, schema and metadata checks, round trips, nulls and precision, signed evidence, and FDA submission status.
A 2026 comparison of entity registration and physical sample logistics across Mosaic, RegMol, Dotmatics and Certara, with modality rules, integration boundaries and a migration reconciliation template.
A 2026 data atlas of FDA BIMO inspections by fiscal year, inspected party and classification, with source-deck revisions, denominator rules, observation families and control priorities.
A 2026 governance framework for AI assistants in pharma and biotech R&D, covering WHO BRIET guidance, project approvals, monitoring, evidence retention, metrics, and tabletop testing.
A 2026 implementation guide to CDISC USDM 4.0, its API and Handbook 1, with a TA/TE/TV/TI/TS mapping, amendment controls, validation gates, and a bounded pilot worksheet.
A 2026 implementation guide to ClinicalTrials.gov API v2 covering REST and bulk access, page-token ingestion, schema drift, record history, provenance, and reproducible trial-intelligence pipelines.
A 2026 pharma control-architecture guide to Claude in Chrome transcripts, including six-year retention, 600-request API sizing, DLP, SIEM, eDiscovery, and Part 11 boundaries.
A 2026 Define-XML 2.1 implementation guide covering field-level metadata controls, FDA version selection, value-level tests, link integrity, and reviewer navigation.
Compare Quartzy, Labguru, SciNote and LabArchives in 2026 across 25 RFP criteria, five workflow tests, inventory traceability, procurement, ELN links, compliance evidence and export paths.
A 2026 operational guide to FDA study data standards version selection, including catalog dates, SDTM, SEND, ADaM, Define-XML, and rejection preflight controls.
A 2026 implementation guide to EMA shortage prevention plans, covering the two-day retrieval rule, field-level data ownership, risk thresholds, ESMP boundaries and mid-2027 readiness.
A 2026 guide to EMA NAM pilot eligibility, four regulatory applicability areas, pathway selection, Module 2.4 package design, and evidence-readiness scoring.
A 2026 evidence matrix for FDA digitally derived measures, covering endpoint roles, verification, validation, missingness, change control, and a stride-length example.
© 2026 IntuitionLabs. All rights reserved.
